Abstract
To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer. A total of 34 reoccurrence or metastatic patients with late stage gastric cancer who were confirmed by histopathology and/or cytology were selected and randomly divided into observational and control groups, of 17 cases each. Patients in the control group were treated with the standard DCF plan, while patients in observational group additionally received nimotuzumab. The short-term and long-term efficacy and adverse reactions in the 2 groups were followed. The objective response rate (ORR) and disease control rate (DCR) were 64.7% (11/17) and 82.4% (14/17) in observational group and 25.0%(4/16) and 37.5%(6/16) in the control group(ORR and DCR between 2 groups, χ2=5.2412, P=0.0221 and χ2=6.9453, P=0.0084). The median progression-free survival (PFS) time and median overall survival (OS) time were 6.50 months and 12.50 months in observational group and 4.50 months and 8.25 months in the control group (P=0.0212; P=0.0255). The main toxic and side effects in the 2 groups were reduced leukocytes and hemoglobin, gastrointestinal reactions and hair loss and these were relieved after symptomatic treatment and nutrition support therapy. There were no differences in the occurrence of toxic and side effects between the 2 groups. Nimotuzumab combined with DCF plan is effective in treating late stage gastric cancer. A larger scale study is now warranted for confirmation of the findings.
Highlights
Gastric cancer, one of common malignant tumors, has high modality in Asian
In order to explore the efficacy of nimotuzumab in the treatment of advanced malignant neoplasm, nimotuzumab combined with chemotherapy was adopted for treating 34 patients with advanced gastric cancer in our hospital since February 2012, with good effect
Chemotherapy was regarded as the main method for treating late gastric cancer (Wei et al, 2013; Liu et al, 2014)
Summary
One of common malignant tumors, has high modality in Asian. Most patients are found in late gastric cancer when clinically diagnosed and lose the chance of surgery because the early clinical symptoms of gastric cancer are easy to be ignored. Multiple studies at home and abroad have proved that nimotuzumab are effective in treatment of head and neck neoplasm, colorectal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC) and breast cancer (Diaz-Miqueli et al, 2013; Lin et al, 2014; Song et al, 2014). Nimotuzumab combined with chemotherapy or radiology is approved for treating head and neck squamous cell carcinoma, glioma in children, nasopharynx cancer (Ciardiello et al, 2008). In order to explore the efficacy of nimotuzumab in the treatment of advanced malignant neoplasm, nimotuzumab combined with chemotherapy was adopted for treating 34 patients with advanced gastric cancer in our hospital since February 2012, with good effect.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
